273 related articles for article (PubMed ID: 33894315)
1. Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL
Xiong Y; Zhu GH; Wang HN; Hu Q; Chen LL; Guan XQ; Li HL; Chen HZ; Tang H; Ge GB
Fitoterapia; 2021 Jul; 152():104909. PubMed ID: 33894315
[TBL] [Abstract][Full Text] [Related]
2. Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CL
Xiong Y; Zhu GH; Zhang YN; Hu Q; Wang HN; Yu HN; Qin XY; Guan XQ; Xiang YW; Tang H; Ge GB
Int J Biol Macromol; 2021 Sep; 187():976-987. PubMed ID: 34333006
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.
Ahmad B; Batool M; Ain QU; Kim MS; Choi S
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502033
[TBL] [Abstract][Full Text] [Related]
4.
Liu H; Ye F; Sun Q; Liang H; Li C; Li S; Lu R; Huang B; Tan W; Lai L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):497-503. PubMed ID: 33491508
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL
Zhang JW; Xiong Y; Wang F; Zhang FM; Yang X; Lin GQ; Tian P; Ge G; Gao D
Eur J Med Chem; 2022 Jan; 228():114030. PubMed ID: 34883292
[TBL] [Abstract][Full Text] [Related]
6. GC-MS, LC-MS/MS, Docking and Molecular Dynamics Approaches to Identify Potential SARS-CoV-2 3-Chymotrypsin-Like Protease Inhibitors from
Zubair MS; Maulana S; Widodo A; Pitopang R; Arba M; Hariono M
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500664
[TBL] [Abstract][Full Text] [Related]
7. Evidence that Ginkgo Biloba could use in the influenza and coronavirus COVID-19 infections.
Ibrahim MA; Ramadan HH; Mohammed RN
J Basic Clin Physiol Pharmacol; 2021 Feb; 32(3):131-143. PubMed ID: 33594843
[TBL] [Abstract][Full Text] [Related]
8. Uncovering the anti-obesity constituents in Ginkgo biloba extract and deciphering their synergistic effects.
Zhang M; Hou XD; Liu W; Wang L; Jiang MF; Hou J; Tang H; Ge GB
Fitoterapia; 2023 Dec; 171():105669. PubMed ID: 37683877
[TBL] [Abstract][Full Text] [Related]
9. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL
Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR
J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470
[TBL] [Abstract][Full Text] [Related]
11. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
[TBL] [Abstract][Full Text] [Related]
12. Potent α-glucosidase inhibitors isolated from Ginkgo biloba leaves.
Sukito A; Tachibana S
Pak J Biol Sci; 2014 Nov; 17(11):1170-8. PubMed ID: 26027162
[TBL] [Abstract][Full Text] [Related]
13. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027
[TBL] [Abstract][Full Text] [Related]
14. Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CL
Wang F; Liu D; Gao D; Yuan J; Zhao J; Yuan S; Cen Y; Lin GQ; Zhao J; Tian P
Int J Biol Macromol; 2024 Apr; 264(Pt 1):130377. PubMed ID: 38395279
[TBL] [Abstract][Full Text] [Related]
15. Ginkgo biloba in the management of the COVID-19 severity.
Al-Kuraishy HM; Al-Gareeb AI; Kaushik A; Kujawska M; Batiha GE
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200188. PubMed ID: 35672257
[TBL] [Abstract][Full Text] [Related]
16. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
[TBL] [Abstract][Full Text] [Related]
17. Biflavones from Ginkgo biloba as inhibitors of human thrombin.
Chen TR; Wei LH; Guan XQ; Huang C; Liu ZY; Wang FJ; Hou J; Jin Q; Liu YF; Wen PH; Zhang SJ; Ge GB; Guo WZ
Bioorg Chem; 2019 Nov; 92():103199. PubMed ID: 31446241
[TBL] [Abstract][Full Text] [Related]
18. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL
Rawson JMO; Duchon A; Nikolaitchik OA; Pathak VK; Hu WS
Viruses; 2021 Jan; 13(2):. PubMed ID: 33498923
[TBL] [Abstract][Full Text] [Related]
19. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.
Ryu YB; Jeong HJ; Kim JH; Kim YM; Park JY; Kim D; Nguyen TT; Park SJ; Chang JS; Park KH; Rho MC; Lee WS
Bioorg Med Chem; 2010 Nov; 18(22):7940-7. PubMed ID: 20934345
[TBL] [Abstract][Full Text] [Related]
20. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
